Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study

References

• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323(13):1239.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.
   PubMed Web of Science ®Google Scholar
• Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020:146(1):206–208.
   PubMedGoogle Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9.
   PubMed Web of Science ®Google Scholar
• Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535.
   PubMed Web of Science ®Google Scholar
• Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
   PubMed Web of Science ®Google Scholar
• Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a Clinical-Therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–407.
   PubMedGoogle Scholar
• McGonagle D, Sharif K, O'Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected pneumonia in wuhan, China. JAMA. 2020;323(11):1061.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41(3):283–297.
   PubMed Web of Science ®Google Scholar
• McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78(9):1167–1178.
   PubMed Web of Science ®Google Scholar
• Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998;160(7):3513–3521.
   PubMed Web of Science ®Google Scholar
• Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164–174.
   PubMed Web of Science ®Google Scholar
• Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019;15(8):491–501.
   PubMed Web of Science ®Google Scholar
• Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–346.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Tahmasebi S, Mahmood A, et al. Th17 and treg cells function in SARS-CoV2 patients compared with healthy controls. J Cell Physiol. 2021;236(4):2829–2839.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Kilian C, Turner JE, et al. Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients. Sci Immunol. 2021;6(56):eabf6692.
   Google Scholar
• Lin X, Fu B, Yin S, et al. ORF8 contributes to cytokine storm during SARS-CoV-2 infection by activating IL-17 pathway. iScience. 2021;24(4):102293.
   PubMed Web of Science ®Google Scholar
• Brasil MdS-. DIRETRIZES PARA DIAGNÓSTICO E TRATAMENTO DA COVID-19. Brasilia 2020. Available from: https://portalarquivos.saude.gov.br/images/pdf/2020/April/18/Diretrizes-Covid19.pdf.
   Google Scholar
• Schoenfeld DA, Bernard GR, Network A, ARDS Network Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30(8):1772–1777.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level Meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829–840.
   PubMed Web of Science ®Google Scholar
• Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the seattle Region - Case series. N Engl J Med. 2020;382(21):2012–2022.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Bianchi L, et al. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the covid-19 era. Expert Opin Biol Ther. 2020;20(8):829–830.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Sanna S, Atzori L, et al. Safety of secukinumab treatment in COVID-19 affected psoriatic patients. Dermatol Ther. 2021;34(1):e14710.
   PubMedGoogle Scholar
• Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors. J Dermatolog Treat. 2022. DOI:https://doi.org/10.1080/09546634.2021.1905766
   Google Scholar
• Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level Meta-analysis. BMJ. 2011;342:d813.
   PubMed Web of Science ®Google Scholar
• Giannis D, Barish MA, Goldin M, the COVID-19 Consortium Group, et al. Incidence of venous thromboembolism and mortality in patients with initial presentation of COVID-19. J Thromb Thrombolysis. 2021;51(4):897–901.
   PubMedGoogle Scholar
• Gratz J, Wiegele M, Maleczek M, et al. Risk of clinically relevant venous thromboembolism in critically ill patients with COVID-19: a systematic review and Meta-Analysis. Front Med (Lausanne). 2021;8:647917.
   PubMedGoogle Scholar
• Kollias A, Kyriakoulis KG, Lagou S, et al. Venous thromboembolism in COVID-19: a systematic review and Meta-analysis. Vasc Med. 2021;26(4):415–425.
   PubMedGoogle Scholar
• Taus F, Salvagno G, Canè S, et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. ATVB. 2020;40(12):2975–2989.
   Google Scholar
• Maione F, Cicala C, Liverani E, et al. IL-17A increases ADP-induced platelet aggregation. Biochem Biophys Res Commun. 2011;408(4):658–662.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yuan J, Yu M, et al. IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome. PLoS One. 2012;7(7):e40641.
   PubMedGoogle Scholar
• Hot A, Lenief V, Miossec P. Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis. 2012;71(5):768–776.
   PubMed Web of Science ®Google Scholar
• Mo JW, Zhang DF, Ji GL, et al. Detection of targets and their mechanisms for early diagnosis of traumatic deep vein thrombosis. Genet Mol Res. 2015;14(1):2413–2421.
   PubMedGoogle Scholar
• Ding P, Zhang S, Yu M, et al. IL-17A promotes the formation of deep vein thrombosis in a mouse model. Int Immunopharmacol. 2018;57:132–138.
   PubMedGoogle Scholar
• de Boer OJ, Li X, Teeling P, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost. 2013;109(2):290–297.
   PubMedGoogle Scholar
• Pulakurthi YS, Pederson JM, Saravu K, et al. Corticosteroid therapy for COVID-19: a systematic review and Meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(20):e25719.
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar